APOE: The Most Studied Alzheimer's Risk Gene
The APOE gene is the single strongest common genetic risk factor for late-onset Alzheimer's disease. Discovered in the early 1990s, the link between APOE e4 and Alzheimer's risk has been replicated in hundreds of studies across diverse populations. It remains the most actionable finding in consumer genetic testing for neurodegeneration risk.
Despite its importance, APOE is widely misunderstood. Carrying one or two copies of the e4 allele increases risk but does not determine fate. This guide explains what the APOE alleles are, how to interpret your genotype, what 23andMe does and does not tell you, and the current state of research on modifying risk.
The Three APOE Alleles
The APOE gene has three common alleles — e2, e3, and e4 — defined by two SNPs on chromosome 19:
- rs429358 (position 44908684) — T or C
- rs7412 (position 44908822) — C or T
The combination of these two SNPs defines the allele:
- e2 — rs429358 = T, rs7412 = T. Frequency: ~7% globally. Generally protective.
- e3 — rs429358 = T, rs7412 = C. Frequency: ~78% globally. Neutral (reference).
- e4 — rs429358 = C, rs7412 = C. Frequency: ~15% globally. Associated with increased risk.
Risk by Genotype
Since everyone carries two APOE alleles, there are six possible genotypes. Their approximate Alzheimer's risk relative to the most common e3/e3 genotype:
- e2/e2 — Reduced risk (~0.6x). Rare genotype (~1% of population).
- e2/e3 — Slightly reduced risk (~0.6x). About 12% of population.
- e3/e3 — Baseline risk (1x). About 60% of population.
- e2/e4 — Approximately 2.6x risk. About 2% of population.
- e3/e4 — Approximately 3.2x risk. About 22% of population.
- e4/e4 — Approximately 12x risk. About 2–3% of population.
These risk multipliers are derived from large meta-analyses but vary by sex, ethnicity, and age of onset. The absolute lifetime risk for e4/e4 carriers is estimated at 50–60%, compared to roughly 10–12% for e3/e3 carriers.
What 23andMe Reports vs Full Clinical Testing
23andMe includes APOE status in its Health + Ancestry reports (where regulatory approvals allow). However, there are important differences between DTC and clinical testing:
- 23andMe reports APOE e4 status but frames results cautiously, with educational context and opt-in access.
- Raw data access — You can determine your full APOE genotype by looking up rs429358 and rs7412 in your downloaded raw data file.
- Clinical testing adds confirmatory genotyping, genetic counseling, and integration with family history and cognitive assessments.
- Rare variants — Neither DTC nor standard clinical APOE testing covers rare pathogenic variants in other genes (APP, PSEN1, PSEN2) that cause early-onset familial Alzheimer's.
Limitations of APOE Testing
It is important to recognize what APOE testing cannot tell you:
- It cannot predict whether or when you will develop Alzheimer's.
- It does not account for the hundreds of other genetic variants that contribute to Alzheimer's risk.
- Risk estimates are based primarily on European-ancestry populations and may not translate directly to other groups.
- Environmental factors, cardiovascular health, education, and lifestyle substantially modify risk and are not captured by genotype alone.
Lifestyle Factors That May Modify Risk
A growing body of research suggests that modifiable risk factors may partly offset APOE e4 risk. The Lancet Commission on dementia prevention identifies 12 modifiable risk factors that collectively account for approximately 40% of dementia cases:
- Regular cardiovascular exercise (150+ minutes per week of moderate activity)
- Blood pressure management (treating hypertension, especially in midlife)
- Hearing loss treatment (hearing aids when indicated)
- Cognitive engagement and social connection
- Managing diabetes, obesity, and smoking
- Limiting excessive alcohol consumption
While none of these interventions have been proven to eliminate genetic risk, the evidence for multi-domain lifestyle modification continues to strengthen.
When to See a Genetic Counselor
Consider genetic counseling if you are thinking about or have already received APOE results, have a strong family history of Alzheimer's (multiple first-degree relatives affected), have early-onset symptoms (before age 65), or are considering APOE testing for family planning or long-term care decisions.
Look up rs429358 and rs7412 using the free SNP Lookup tool to check your APOE-defining SNPs and see population frequency data. For a complete genomic profile, explore the Genomics Dashboard.